| Literature DB >> 29385715 |
Franka Klatte-Schulz1,2, Susann Minkwitz3,4, Aysha Schmock5, Nicole Bormann6,7, Alper Kurtoglu8, Serafeim Tsitsilonis9, Sebastian Manegold10, Britt Wildemann11,12.
Abstract
Reasons for the development of chronic tendon pathologies are still under debate and more basic knowledge is needed about the different diseases. The aim of the present study was therefore to characterize different acute and chronic Achilles tendon disorders. Achilles tendon samples from patients with chronic tendinopathy (n = 7), chronic ruptures (n = 6), acute ruptures (n = 13), and intact tendons (n = 4) were analyzed. The histological score investigating pathological changes was significantly increased in tendinopathy and chronic ruptures compared to acute ruptures. Inflammatory infiltration was detected by immunohistochemistry in all tendon pathology groups, but was significantly lower in tendinopathy compared to chronic ruptures. Quantitative real-time PCR (qRT-PCR) analysis revealed significantly altered expression of genes related to collagens and matrix modeling/remodeling (matrix metalloproteinases, tissue inhibitors of metalloproteinases) in tendinopathy and chronic ruptures compared to intact tendons and/or acute ruptures. In all three tendon pathology groups markers of inflammation (interleukin (IL) 1β, tumor necrosis factor α, IL6, IL10, IL33, soluble ST2, transforming growth factor β1, cyclooxygenase 2), inflammatory cells (cluster of differentaition (CD) 3, CD68, CD80, CD206), fat metabolism (fatty acid binding protein 4, peroxisome proliferator-activated receptor γ, CCAAT/enhancer-binding protein α, adiponectin), and innervation (protein gene product 9.5, growth associated protein 43, macrophage migration inhibitory factor) were detectable, but only in acute ruptures significantly regulated compared to intact tendons. The study gives an insight into structural and molecular changes of pathological processes in tendons and might be used to identify targets for future therapy of tendon pathologies.Entities:
Keywords: acute rupture; chronic tendon pathologies; fat; human; inflammation; innervation; matrix; modeling/remodeling; tendon structure
Mesh:
Substances:
Year: 2018 PMID: 29385715 PMCID: PMC5855626 DOI: 10.3390/ijms19020404
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Exemplary histologies of intact tendons, tendinopathic tendons, chronic ruptures and acute ruptures using Movat Pentachrome (MP) staining (tendon architecture, glycosaminoglycan (GAG) and fat tissue (lipid vacuoles)), α smooth muscle actin (αSMA) staining (vascularity) and Hematoxylin Eosin (HE) staining (cellularity). F: fat tissue, V: vessels, C: cell clusters. The Movat Pentachrome staining used stains collagen in yellow to brown, mature collagen in red [31], GAG ground substance in turquois, cell nuclei in blue to black and cytoplasm stains reddish.
Figure 2Evaluation of histological score: (A) Total histological score reaching 18 points as maximum, which would indicate a highly degenerated tendon. (B) Tendon architecture as indicator for the disturbance of the tendon structure (0–3 points). (C) Amount of aligned collagen quantified using ImageJ (0–100%). (D) GAG content (0–3 points, MP staining). (E) Fat tissue quantified using ImageJ (0–100%, MP staining). (F) Cellularity (0–3 points, HE staining). (G) Vascularity (0–3 points, αSMA staining). (H) Inflammatory cells (not included in histological score, CD45 staining). Data are given as individual dot plots with median and interquartile range.
Figure 3Exemplary images of inflammatory cell infiltration visualized by immunohistological CD45 (leucocytes) and CD68 (monocytes/macrophages) staining in tendinopathic tendons, chronic ruptures and acute ruptures.
Figure 4Relative gene expression of collagens (A–C), MMPs (D–H) and TIMPs (I–L) in tendinopathic tendons, chronic ruptures and acute ruptures given as fold to intact tendon tissue (horizontal line, mean value = 1). qRT-PCR data were normalized to the expression of the house keeping gene 18S rRNA with efficiency correction and presented as fold change to the mean of the intact tendons. Results are shown as individual dot plots with median and interquartile range. Significant differences between the intact tendons and the three tendon pathology groups are marked with a star (*) above the intact tendon and the respective significant group (T: tendinopathy, C: chronic ruptures, A: acute ruptures) and the p-value. The vertical dashed line separates the intact group from the tendon pathology groups. Significant differences between the three tendon pathology groups are marked with a spanning line above the groups and the individual p-values. p ≤ 0.05 was considered as statistically significant.
Figure 5Relative gene expression of TNMD (A), the inflammatory cytokines IL33, IL6 and IL10 (B–D), the immune cell marker CD68 (E), the nerve markers MIF and PGP9.5 (F–G), the pain marker COX2 (H), and the fat markers FABP4, PPARγ and CEBPα (I–K) in tendinopathic tendons, chronic ruptures and acute ruptures given as fold to intact tendon tissue (horizontal line, mean value = 1). qRT-PCR data were normalized to the expression of the house keeping gene 18S rRNA with efficiency correction and presented as fold change to the mean of the intact tendons. Results are shown as individual dot plots with median and interquartile range. Significant differences between the intact tendons and the three tendon pathology groups are marked with a star (*) above the intact tendon and the respective significant group (T: tendinopathy, C: chronic ruptures, A: acute ruptures) and the p-value. The vertical dashed line separates the intact group from the tendon pathology groups. Significant differences between the three tendon pathology groups are marked with a spanning line above the groups and the individual p-values. p ≤ 0.05 was considered as statistically significant.
Donor demographics.
| Group | Age (Mean ± SD) | BMI (Mean ± SD) | Sex (Female/Male) | |
|---|---|---|---|---|
| Tendinopathy | 7 | 45.3 ± 7.9 years | 26.8 ± 5.2 | 3/4 |
| Chronic Rupture | 6 | 52.2 ± 12.6 years * | 28.6 ± 5.2 | 1/5 |
| Acute Rupture | 13 | 32.0 ± 3.1 years * | 23.5 ± 1.9 | 2/11 |
| Intact (patient) | 4 | 37.8 ± 12.8 years | 30.5 ± 3.5 | 2/2 |
| Intact (cadaver) | 5 | 83.4 ± 2.9 years | - | 3/2 |
* Significantly different (p = 0.005).
qRT-PCR Primer.
| Gene | Accession No. | Primer Sequence |
|---|---|---|
| NM_022551 | Forward: 5′ CGGAAAATAGCCTTTGCCATC 3′ | |
| Reverse: 5′ AGTTCTCCCGCCCTCTTGGT 3′ | ||
| NM_000088.3 | Forward: 5′ TGACCTCAAGATGTGCCACT 3′ | |
| Reverse: 5′ ACCAGACATGCCTCTTGTCC 3′ | ||
| NM_000090.3 | Forward: 5′ GCTGGCATCAAAGGACATCG 3′ | |
| Reverse: 5′ TGTTACCTCGAGGCCCTGGT 3′ | ||
| NM_000393 | Forward: 5′ AGAAGCCTCCCAGAACATCA 3′ | |
| Reverse: 5′ ACAGTCTTGCCCACATTTCC 3′ | ||
| NM_002421.3 | Forward: 5′ CACGCCAGATTTGCCAAGAG 3′ | |
| Reverse: 5′ GTCCCGATGATCTCCCCTGA 3′ | ||
| NM_ 004530 | Forward: 5′ TGGATGATGCCTTTGCTCGT 3′ | |
| Reverse: 5′ CCAGGAGTCCGTCCTTACCG 3′ | ||
| NM_002422.3 | Forward: 5′ TGGGCCAGGGATTAATGGAG 3′ | |
| Reverse: 5′ GGCCAATTTCATGAGCAGCA 3′ | ||
| NM_004994.2 | Forward: 5′ GGGACGCAGACATCGTCATC 3′ | |
| Reverse: 5′ GGGACCACAACTCGTCATCG 3′ | ||
| NM_ 002425 | Forward: 5′ CCACCTGGACCTGGGCTTTA 3′ | |
| Reverse: 5′ GAACTGGGCGAGCTCTGTGA 3′ | ||
| NM_002427.3 | Forward: 5′ CCTTCCCAGTGGTGGTGATG 3′ | |
| Reverse: 5′ CGGAGCCTCTCAGTCATGGA 3′ | ||
| NM_003254.2 | Forward: 5′ TTGGCTGTGAGGAATGCACA 3′ | |
| Reverse: 5′ AAGGTGACGGGACTGGAAGC 3′ | ||
| NM_003255.4 | Forward: 5′ CCTGAGCACCACCCAGAAGA 3′ | |
| Reverse: 5′ TCCATCCAGAGGCACTCGTC 3′ | ||
| NM_000362.4 | Forward: 5′ CCGAGGCTTCACCAAGATGC 3′ | |
| Reverse: 5′ GCCATCATAGACGCGACCTG 3′ | ||
| NM_003256.3 | Forward: 5′ GAAGCCAACAGCCAGAAGCA 3′ | |
| Reverse: 5′ TTCCCTCTGCACCAAGGACA 3′ | ||
| NM_022144.2 | Forward: 5′ TTGAAGACCCACGAAGTAGA 3′ | |
| Reverse: 5′ ATGACATGGAGCACACTTTC 3′ | ||
| NM_033439 | Forward: 5′ CCAACAGAAGGCCAAAGAAG 3′ | |
| Reverse: 5′ AAGGCAAAGCACTCCACAGT 3′ | ||
| NM_003856 | Forward: 5′ CAACAAGAGGAAGGGCAAAA 3′ | |
| Reverse: 5′ CAAATTCAGGGCCAGACAGT 3′ | ||
| NM_000576 | Forward: 5′ TCCAGGAGAATGACCTGAGC 3′ | |
| Reverse: 5′ GTGATCGTACAGGTGCATCG 3′ | ||
| NM_000594 | Forward: 5′ AGCCCATGTTGTAGCAAACC 3′ | |
| Reverse: 5′ GAGGTACAGGCCCTCTGATG 3′ | ||
| NM_000600 | Forward: 5′ TGAGGAGACTTGCCTGGTGA 3′ | |
| Reverse: 5′ TTGGGTCAGGGGTGGTTATT 3′ | ||
| NM_000572 | Forward: 5′ TGAGAACAGCTGCACCCACT 3′ | |
| Reverse: 5′ GGCAACCCAGGTAACCCTTA 3′ | ||
| NM_000660.4 | Forward: 5′ AAGGACCTCGGCTGGAAGTG 3′ | |
| Reverse: 5′ AGGGCCAGGACCTTGCTGTA 3′ | ||
| NM_000073 | Forward: 5′ CTGGGAAGTAATGCCAAGGA 3′ | |
| Reverse: 5′ CCAACAGCAAGGACGAAAAT 3′ | ||
| NM_001040059 | Forward: 5′ CCACCTGCTTCTCTCATTCC 3′ | |
| Reverse: 5′ ATTGTACTCCACCGCCATGT 3′ | ||
| NM_005191 | Forward: 5′ GCAGGGAACATCACCATCCA 3′ | |
| Reverse: 5′ CAGGACAGCGTTGCCACTTC 3′ | ||
| NM_002438 | Forward: 5′ ACTGGGGCCAAGCTTCTCTG 3′ | |
| Reverse: 5′ CACAGCCACGTCCCTTCAAC 3′ | ||
| NM_002415 | Forward: 5′ GGTTCCTCTCCGAGCTCACC 3′ | |
| Reverse: 5′ TAGACCCTGTCCGGGCTGAT 3′ | ||
| NM_004181 | Forward: 5′ CCATACAGGCAGCCCATGAT 3′ | |
| Reverse: 5′ AGACCTTGGCAGCGTCCTTC 3′ | ||
| NM_002045 | Forward: 5′ CCGGCAAAGCAGGAGAAACT 3′ | |
| Reverse: 5′ TGGAGGACGGCGAGTTATCA 3′ | ||
| NM_000963 | Forward: 5′ TAGAGCCCTTCCTCCTGTGC 3′ | |
| Reverse: 5′ TGGGGATCAGGGATGAACTT 3′ | ||
| NM_001442 | Forward: 5′ ACTGGGCCAGGAATTTGACG 3′ | |
| Reverse: 5′ ATGACGCATTCCACCACCAG 3′ | ||
| NM_015869 | Forward: 5′ AAAGTCCTTCCCGCTGACCA 3′ | |
| Reverse: 5′ GGCCACCTCTTTGCTCTGCT 3′ | ||
| NM_004797 | Forward: 5′ TGACCAGGAAACCACGACTCA 3′ | |
| Reverse: 5′ CCGATGTCTCCCTTAGGACCA 3′ | ||
| NM_004364 | Forward: 5′ AAGGCCAAGAAGTCGGTGGA 3′ | |
| Reverse: 5′ GGCGGTCATTGTCACTGGTC 3′ | ||
| Commercial Quantitect primer Assay Hs_SCXB_2_SG | ||